Skip to main content
Clinical Trials/NCT01734798
NCT01734798
Completed
Phase 3

Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer

Cairo University1 site in 1 country198 target enrollmentDecember 2002

Overview

Phase
Phase 3
Intervention
Radiation
Conditions
Locally Advanced Bladder Cancer
Sponsor
Cairo University
Enrollment
198
Locations
1
Primary Endpoint
Comparison of the disease-free survival and overall survival of post-operative radiotherapy , adjuvant chemotherapy and the combined modalities [radiotherapy and chemotherapy] after radical cystectomy
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

Radical Cystectomy is still the standard treatment in muscle-invasive Bladder cancer. Local recurrence is still the major cause of failure together with distant metastasis. postoperative radiotherapy succeeded to decrease the local recurrence and hence improved the overall survival. Adjuvant chemotherapy has also improved the survival in different studies. This study is performed to test the efficacy and toxicity of adding the two modalities together compared to each modality alone.

Registry
clinicaltrials.gov
Start Date
December 2002
End Date
November 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mohamed s. Zaghloul

Professor of Radiation Oncology

Cairo University

Eligibility Criteria

Inclusion Criteria

  • Patients not more than 70 years old.
  • Radical cystectomy performed within 42 days with no microscopic or macroscopic residual after surgery (negative surgical safety margins)
  • Having one or more of the risk factors ( P3b,P4a,G3 and /or positive LN)
  • ECOG Performance Scale (0-2).
  • Adequate liver functions.
  • Adequate renal function serum (creatinine \< 1.5 mg).
  • No evidence of distant metastasis or other malignancy.

Exclusion Criteria

  • patients who received radiotherapy or chemotherapy prior to radical cystectomy

Arms & Interventions

Arm 1

post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks

Intervention: Radiation

Arm 2

adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy

Intervention: Radiotherapy and Drug

Arm 3

Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy

Intervention: gemcitabine and cisplatin

Outcomes

Primary Outcomes

Comparison of the disease-free survival and overall survival of post-operative radiotherapy , adjuvant chemotherapy and the combined modalities [radiotherapy and chemotherapy] after radical cystectomy

Time Frame: Five-year overall and disease-free survival.

Regular follow up is performed every 2 months in the first 2 years postcystectomy and every 6 months thereafter. Periodical CT pelvis is performed every 6 months in the first 2 years and yearly thereafter. The other appropriate radiological studies are performed in response to patients' symptoms and signs. Treatment side effects (immediate and late) are reported in each follow up visit.

Secondary Outcomes

  • comparison of the Local recurrence rate in the three Arms(Five year local pelvic control rate)

Study Sites (1)

Loading locations...

Similar Trials